TIDMPRM

RNS Number : 1111C

Proteome Sciences PLC

11 April 2017

Proteome Sciences plc

(the "Company" or the "Group")

Director Dealing and Total Voting Rights

Proteome Sciences plc (AIM:PRM) announces that on 7 April 2017, Ian Pike, Chief Scientific Officer of the Company and a former employee exercised 165,583 and 158,308 options over ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") respectively.

Application has been made to the London Stock Exchange for the 323,891 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 18 April 2017.

After Admission, the total number of Ordinary Shares in issue will be 294,648,723, all with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 
 For further information: 
 
  Proteome Sciences plc 
 Dr Jeremy Haigh, Chief Executive Officer Tel: 
  +44 (0)1932 865065 
 Dr Ian Pike, Chief Scientific 
  Officer 
 Geoff Ellis, Finance Director 
 
   finnCap Limited (Nominated 
   Adviser/Broker)                            Tel: +44 (0)20 7220 
   Geoff Nash/James Thompson                  0500 
 Tony Quirke (broking) 
 
  IFC Advisory (Financial PR and IR) 
 Tim Metcalfe/Graham                        Tel: +44 (0)20 3053 
  Herring/Miles Nolan                        8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                      Ian Pike 
2.  Reason for the Notification 
a)  Position/status                                           Chief Scientific Officer 
b)  Initial notification/Amendment                            Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                      Proteome Sciences plc 
b)  LEI                                                       n/a 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 
a)  Description of the Financial instrument, type of          Options over Ordinary Shares of 1p each 
    instrument 
    Identification code                                       GB0003104196 
b)  Nature of the transaction                                 Exercise of options 
c)  Price(s) and volume(s)                                    165,583 options 
d)  Aggregated information: 
     -- Aggregated volume                                      165,583 Options over Ordinary Shares of 1p each 
     -- Price                                                  exercised 
e)  Date of the transaction                                   7 April 2017 
f)  Place of the transaction                                  London Stock Exchange, AIM Market (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFMGMDKGZGNZM

(END) Dow Jones Newswires

April 11, 2017 02:00 ET (06:00 GMT)

Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Proteome Sciences Charts.
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Proteome Sciences Charts.